November 12th, 2003 — Pittsburgh — TissueInformatics.Inc — "The World's Automated Pathology Company®".

TissueInformatics.Inc (www.TissueInformatics.com), the World's Automated Pathology Company, announced today that industry giant L'Oréal, has licensed TissueInformatics TissueAnalytics Software for the automated pathology slide screening of tissue engineered skin within L'Oréal's laboratories.

With revenues of US$17 billion, 50,000 employees, 290 subsidiaries in 130 countries, L'Oréal is the World's Largest Skin Care company.

TissueInformatics is a pioneer in the field of automated tissue analysis and automated pathology slide screening. TissueInformatics is currently expanding its automated pathology slide screening software to enable the automated slide screening of over 43 tissues of Rat, Dog, Monkey and Mouse. TissueInformatics holds many patents including the patent for construction of tissue databases of normality necessary for automated pathology slide screening.

L'Oréal has developed a tissue engineered skin termed "EpiSkin" which has many practical life enhancing applications. Tissue engineered skin may be used in the treatment of wounds, the shortening of the healing process, and may also be used as a substitute testing medium in place of natural skin.

To manufacture and utilize EpiSkin effectively in its laboratories, L'Oréal will implement TissueInformatics TissueAnalytics software to enable the automated pathology slide screening of specific histological structural features of EpiSkin and compare these measurements between test and control tissues. This will allow L'Oreal to ensure the engineered tissue is within acceptable limits of normality and accelerate their laboratory operations.

TissueInformatics has the most advanced automated technology and methods for the robust identification, classification and characterization of tissues. The implementation of TissueInformatics software will enable L'Oréal Corporate Research and Development to assure the quantification of the morphology of its reconstructed skin models with a high degree of accuracy and precision. TissueInformatics software will enable L'Oréal a high level of quality control and quality assurance, whether for research and development use or for their validated product currently manufactured and sold by its subsidiary EPISKIN SNC.

"We are very pleased to have L'Oreal, the world's leader in skin care, as TissueInformatics' preferred partner. The anticipated growth of the engineered tissue market is expected to create a $1 billion market opportunity and the tissue engineered skin segment is expected to grow upwards of 40% annually by 2010. We are very excited L'Oréal, the world's largest skin care company, has recognized TissueInformatics as the leader in automated pathology slide screening." said Peter Johnson, Chairman and CEO of TissueInformatics.

Funded by notable investors such as the Aurora Funds, Birchmere Ventures, the Future Fund, Informax, Manulife Financial, Motorola, Smithfield Trust and Techno Venture Management (TVM), TissueInformatics accelerates the toxicology analysis and drug discovery processes by providing a broad range of tissue analysis software, tissue analysis services, and target discovery solutions to the pharmaceutical, biotechnology and CRO industries.

For further information, please visit www.TissueInformatics.com or contact Todd A. Joron, Senior Vice President at TJoron@TissueInformatics.com.

###
Statements in this press release that are not strictly historical are "forward-looking" statements, which involve a high degree of risk and uncertainty. Such statements are only predictions, and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include, but are not limited to, risks associated with TissueInformatics.Inc's (the "Company's") dependence upon the creation of strategic alliances with providers for complementary services and products and the need to keep pace with rapid technological change, the Company's dependence for future revenues on its ability to increase sales of its tissue imaging and analysis applications, the development and availability of competitive products or technologies, and the Company's dependence on patents and its ability to defend its intellectual property rights. The Company specifically disclaims any intention or duty to update any forward-looking statements, and these statements represent the Company's current outlook as of the date given.

Todd A. Joron
Senior Vice President
Sales & Marketing
(412) 327-4354
TJoron@TissueInformatics.com

Back to Portfolio News